EU/3/07/462
About
Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in October 2019 on request of the sponsor.
On 2 August 2007, orphan designation (EU/3/07/462) was granted by the European Commission to SuppreMol GmbH, Germany, for recombinant human soluble Fc-gamma receptor II b for the treatment of idiopathic thrombocytopenic purpura.
The sponsorship was transferred to Baxalta Innovations GmbH, Austria in June 2017.
Key facts
Active substance |
Recombinant human soluble Fc-gamma receptor II b
|
Disease / condition |
Treatment of idiopathic thrombocytopenic purpura
|
Date of first decision |
02/08/2007
|
Outcome |
Withdrawn
|
EU designation number |
EU/3/07/462
|
Sponsor's contact details
Industriestrasse 67
A-1221 Vienna
Austria
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.